The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy
Clinical trial NCT04782622 · UNKNOWN
Trial details
- NCT number
- NCT04782622
- Sponsor
- The Affiliated Hospital of Qingdao University
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-03-01
- Primary completion
- 2022-01-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.